이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

MacroGenics 과거 수익 실적

과거 기준 확인 0/6

MacroGenics은 연평균 21.8%의 비율로 수입이 증가해 온 반면, Biotechs 산업은 연평균 15.5%의 비율로 수입이 증가했습니다. 매출은 연평균 9.9%의 비율로 증가했습니다.

주요 정보

21.8%

수익 성장률

28.0%

EPS 성장률

Biotechs 산업 성장	17.0%
매출 성장률	9.9%
자기자본 수익률	-21.9%
순이익	-53.6%
최근 수익 업데이트	31 Mar 2024

최근 과거 실적 업데이트

Recent updates

MacroGenics, Inc.'s (NASDAQ:MGNX) 81% Dip In Price Shows Sentiment Is Matching Revenues

May 13

MacroGenics: Strong Likelihood Bad News Has Caused Overreaction (Rating Upgrade)

May 13

MacroGenics: Positive Safety Update Leads To Two Major Inflection Points In 2024

Apr 05

MacroGenics, Inc. (NASDAQ:MGNX) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Feb 28

Analysts' Revenue Estimates For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher

Oct 25

MacroGenics: No Near-Term Catalysts

Oct 11

Israel Englander and his Millennium fund disclose 5.2% passive stake in MacroGenics

Sep 02

MacroGenics Q2 2022 Earnings Preview

Aug 05

Companies Like MacroGenics (NASDAQ:MGNX) Could Be Quite Risky

Jul 25

MacroGenics halts mid-stage head and neck cancer study after fatalities

Jul 11

The Consensus EPS Estimates For MacroGenics, Inc. (NASDAQ:MGNX) Just Fell Dramatically

May 09

We're Keeping An Eye On MacroGenics' (NASDAQ:MGNX) Cash Burn Rate

Apr 12

MacroGenics: Facing Considerable Headwinds From Unsatisfactory Trials

Feb 25

Estimating The Intrinsic Value Of MacroGenics, Inc. (NASDAQ:MGNX)

Feb 18

We're Not Very Worried About MacroGenics' (NASDAQ:MGNX) Cash Burn Rate

Nov 21

MacroGenics: Revisiting Our Pipeline And Investment Analysis

Aug 10

MacroGenics, Inc. (NASDAQ:MGNX) Analysts Are More Bearish Than They Used To Be

Aug 03

MacroGenics collaborates with Zai Lab to develop bispecific antibodies in oncology

Jun 16

수익 및 비용 분석

MacroGenics 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

NasdaqGS:MGNX 수익, 비용 및 수입 (USD Millions )
날짜	수익	수익	G+A 비용
31 Mar 24	43	-23	53
31 Dec 23	59	-9	52
30 Sep 23	121	50	53
30 Jun 23	152	7	56
31 Mar 23	165	-91	56
31 Dec 22	152	-120	59
30 Sep 22	93	-191	61
30 Jun 22	67	-219	63
31 Mar 22	72	-217	64
31 Dec 21	77	-202	63
30 Sep 21	116	-146	60
30 Jun 21	119	-129	53
31 Mar 21	108	-136	48
31 Dec 20	105	-130	43
30 Sep 20	77	-158	42
30 Jun 20	78	-167	44
31 Mar 20	68	-152	46
31 Dec 19	64	-152	46
30 Sep 19	55	-166	45
30 Jun 19	57	-155	42
31 Mar 19	65	-167	41
31 Dec 18	60	-171	41
30 Sep 18	197	-21	38
30 Jun 18	178	-34	37
31 Mar 18	160	-32	34
31 Dec 17	158	-20	33
30 Sep 17	10	-160	33
30 Jun 17	12	-147	32
31 Mar 17	91	-66	31
31 Dec 16	92	-59	30
30 Sep 16	95	-52	27
30 Jun 16	106	-34	26
31 Mar 16	32	-96	24
31 Dec 15	101	-20	23
30 Sep 15	98	-11	21
30 Jun 15	102	1	19
31 Mar 15	104	10	17
31 Dec 14	48	-38	16
30 Sep 14	57	-20	15
30 Jun 14	59	-15	13
31 Mar 14	62	0	11
31 Dec 13	58	0	11
30 Sep 13	53	0	11
30 Jun 13	49	0	10

양질의 수익: MGNX 은(는) 현재 수익성이 없습니다.

이익 마진 증가: MGNX 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: MGNX 은(는) 수익성이 없지만 지난 5년 동안 연간 21.8% 의 비율로 손실을 줄였습니다.

성장 가속화: 현재 수익성이 없기 때문에 MGNX 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: MGNX 은(는) 수익성이 없어 지난 해 수익 성장을 Biotechs 업계( -14.4% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: MGNX 현재 수익성이 없기 때문에 마이너스 자본 수익률( -21.89% )을 갖습니다.

MacroGenics 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Full year 2023 earnings: EPS and revenues miss analyst expectations

MacroGenics, Inc. to Report Q4, 2023 Results on Mar 07, 2024

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

MacroGenics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Recent updates

Consensus EPS estimates fall by 18%

MacroGenics, Inc.'s (NASDAQ:MGNX) 81% Dip In Price Shows Sentiment Is Matching Revenues

MacroGenics: Strong Likelihood Bad News Has Caused Overreaction (Rating Upgrade)

First quarter 2024 earnings: EPS and revenues miss analyst expectations

MacroGenics: Positive Safety Update Leads To Two Major Inflection Points In 2024

MacroGenics, Inc. Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures

New minor risk - Share price stability

Consensus revenue estimates fall by 21%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Investor sentiment improves as stock rises 23%

Price target increased by 9.9% to US$16.00

MacroGenics, Inc. (NASDAQ:MGNX) Surges 27% Yet Its Low P/S Is No Reason For Excitement

MacroGenics, Inc. to Report Q4, 2023 Results on Mar 07, 2024

President exercised options and sold US$250k worth of stock

MacroGenics: Trying To Build A Better Everything

Price target increased by 8.1% to US$14.78

Insider notifies of intention to sell stock

Insider notifies of intention to sell stock

Investor sentiment improves as stock rises 19%

Price target increased by 12% to US$14.33

Insider notifies of intention to sell stock

There's No Escaping MacroGenics, Inc.'s (NASDAQ:MGNX) Muted Revenues

Insider notifies of intention to sell stock

Consensus EPS estimates increase by 17%, revenue downgraded

Investor sentiment improves as stock rises 18%

Consensus revenue estimates decrease by 25%, EPS upgraded

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

MacroGenics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Investor sentiment deteriorates as stock falls 15%

Insider recently bought US$74k worth of stock

Investor sentiment deteriorates as stock falls 16%

Consensus revenue estimates increase by 17%

New minor risk - Share price stability

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

MacroGenics, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Consensus EPS estimates fall by 13%

Benign Growth For MacroGenics, Inc. (NASDAQ:MGNX) Underpins Its Share Price

Consensus revenue estimates fall by 31%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

MacroGenics, Inc. to Report Q1, 2023 Results on May 09, 2023

Price target increased by 11% to US$11.75

Consensus revenue estimates increase by 42%

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Analyst Forecasts For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher

Consensus EPS estimates fall by 10%

Macrogenics Announces Preliminary Clinical Results from Single Arm Study of Lorigerlimab in Patients

Here's Why MacroGenics (NASDAQ:MGNX) Must Use Its Cash Wisely

Price target decreased to US$10.40

MacroGenics, Inc. Appoints Dr. Margaret Liu and Meenu Chhabra Karson to Board of Directors

Macrogenics, Inc. Approves the Appointment of Margaret Liu, M.D. to Serve as Director

MacroGenics Earns $60 Million Milestone with U.S. FDA Approval of Teplizumab

Price target increased to US$12.33

Consensus revenue estimates increase by 11%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

MacroGenics, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Analysts' Revenue Estimates For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher

Consensus forecasts updated

MacroGenics: No Near-Term Catalysts

Price target decreased to US$10.72

Israel Englander and his Millennium fund disclose 5.2% passive stake in MacroGenics

Consensus revenue estimates increase by 11%

Consensus revenue estimates increase by 33%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

MacroGenics Q2 2022 Earnings Preview

MacroGenics, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Companies Like MacroGenics (NASDAQ:MGNX) Could Be Quite Risky

Price target decreased to US$25.33

MacroGenics halts mid-stage head and neck cancer study after fatalities

MacroGenics, Inc. Announces Closure of CP-MGA271-06 Study Evaluating Enoblituzumab plus Checkpoint Inhibition in Head and Neck Cancer